Public, NASDAQ:IDRA
NASDAQ Global Market
IDERA PHARMACEUTICALS, INC. : Idera Pharmaceuticals to Present at BIO CEO ...
Date: Mon, 06 Feb 2012 14:13:36 GMT
Tags:
IDERA PHARMACEUTICALS, INC. : Idera Pharmaceuticals to Present at BIO CEO ...
4-traders (press release) - Feb 6, 2012
4-traders (press release) - Feb 6, 2012
Idera Pharmaceuticals (Nasdaq: IDRA) today announced that Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer, is scheduled to present at the 14 th Annual BIO CEO & Investor Conference on February 13 th at 10:30 am ET.
CORRECTING and REPLACING Idera Pharmaceuticals to Present at BIO CEO ... - MarketWatch (press release)Idera Pharmaceuticals Reveals Results Of Phase 1b Trial Of IMO-2055 -Quick Facts
Date: Fri, 20 Jan 2012 13:19:47 GMT
Tags:
Idera Pharmaceuticals Reveals Results Of Phase 1b Trial Of IMO-2055 -Quick Facts
NASDAQ - Jan 20, 2012
NASDAQ - Jan 20, 2012
(RTTNews.com) - Idera Pharmaceuticals Inc (IDRA) Friday announced favorable safety and efficacy results from a Phase 1b study of IMO-2055, a TLR9 agonist, in combination with Tarceva and Avastin, in thirty-six patients with advanced non-small cell lung ...
Idera Pharmaceuticals Announces Favorable Data from Phase 1b Study of IMO-2055 ... - MarketWatch (press release)Idera Pharmaceuticals Inc Announces FDA Authorization to Proceed with Phase 2 Clinical Trial of IMO-3100 in Patients with Psoriasis
Date: Thu, 01 Dec 2011 13:30:00 GMT
Tags:
Idera Pharmaceuticals Inc Announces FDA Authorization to Proceed with Phase 2 Clinical Trial of IMO-3100 in Patients with Psoriasis
Reuters Key Development - Dec 1, 2011
Reuters Key Development - Dec 1, 2011
Idera Pharmaceuticals Inc Presents Preclinical Data On Gene-silencing Oligonucleotides At EuroTIDES 2011 Conference
Date: Tue, 15 Nov 2011 13:00:00 GMT
Tags:
Idera Pharmaceuticals Inc Presents Preclinical Data On Gene-silencing Oligonucleotides At EuroTIDES 2011 Conference
Reuters Key Development - Nov 15, 2011
Reuters Key Development - Nov 15, 2011
Idera Pharmaceuticals Inc Completes $9.5 Million Financing
Date: Fri, 04 Nov 2011 20:15:00 GMT
Tags:
DIARY-U.S. MEETINGS/WEEK AHEAD
Date: Wed, 08 Feb 2012 13:25:18 GMT
Tags:
CORRECTING and REPLACING Idera Pharmaceuticals to Present at BIO CEO Conference February 13th, 2012
Date: Mon, 06 Feb 2012 15:23:00 GMT
Tags:
[Business Wire] - Headline of release should read: Idera Pharmaceuticals to Present at BIO CEO Conference February 13th, 2012 (sted Idera Pharmaceuticals to Present at BIO CEO Conference February 14
Idera Pharmaceuticals Announces Favorable Data from Phase 1b Study of IMO-2055 in Combination with Tarceva® and Avastin® in Patients with Advanced Non-Small Cell Lung Cancer
Date: Fri, 20 Jan 2012 13:00:00 GMT
Tags:
[Business Wire] - Idera Pharmaceuticals, Inc. today announced favorable safety and efficacy results from a Phase 1b study of IMO-2055, a TLR9 agonist, in combination with Tarceva® and Avastin® in thirty-six patients with advanced non-small cell lung cancer who have previously failed one or more prior therapies.
Idera Pharmaceuticals Announces Selection of Toll-like Receptor Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck
Date: Mon, 09 Jan 2012 12:00:00 GMT
Tags:
[Business Wire] - Idera Pharmaceuticals, Inc. today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor agonis
2012 Preview: Cancer Immunotherapy Catalysts
Date: Thu, 15 Dec 2011 16:17:35 GMT
Tags: